Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Mirum: Rare Disease Play With Upcoming Catalysts
08:00am, Tuesday, 18'th May 2021
Mirum: Rare Disease Play With Upcoming Catalysts
Albireo Pharma (ALBO) CEO Ron Cooper on Q1 2021 Results - Earnings Call Transcript
07:07am, Saturday, 08'th May 2021
Albireo Pharma (ALBO) CEO Ron Cooper on Q1 2021 Results - Earnings Call Transcript
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 07'th May 2021
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement
Albireo Reports Q1 Financial Results and Business Update
08:30am, Thursday, 06'th May 2021
– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU–
Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
04:38pm, Monday, 26'th Apr 2021
Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
08:30am, Tuesday, 13'th Apr 2021
– Appointment strengthens leadership team as the Company readies for potential global odevixibat launch and progresses multiple clinical development programs –
Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
08:30am, Tuesday, 06'th Apr 2021
BOSTON, April 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced participation in the
Albireo Announces First Patients Dosed in Two New Studies
08:30am, Thursday, 25'th Mar 2021
– Dosed first patients in Phase 1 study with new product candidate A3907 –
Albireo Spotlights Global Patient Communities on Rare Disease Day
08:30am, Friday, 26'th Feb 2021
– Calls to unite global communities affected by rare diseases –
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2020 Results - Earnings Call Transcript
08:36pm, Thursday, 25'th Feb 2021
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q4 2020 Results - Earnings Call Transcript
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
08:00am, Thursday, 25'th Feb 2021
– NDA and MAA for odevixibat accepted, on track for anticipated H2 21 launch –
Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
08:30am, Tuesday, 23'rd Feb 2021
BOSTON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare pediatric liver disease company developing novel bile acid modulators, today announced participatio
Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
08:30am, Thursday, 18'th Feb 2021
Conference call and webcast to be held at 10:00 a.m. ET Conference call and webcast to be held at 10:00 a.m. ET
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 17'th Feb 2021
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducemen
Albireo Presents Odevixibat Commercialization Road to $1 Billion
08:30am, Thursday, 11'th Feb 2021
– Company outlining large global rare cholestatic liver disease opportunity –
